Remote patient management market set to thrive

The U.S. market for remote patient management (RPM) is projected to grow by 13 percent over the next five years, according to an analysis from Frost & Sullivan.

Researchers considered the RPM market for home healthcare and post-acute care and chronic condition management and disease management.

The current clinical need for remote patient management is limited, new opportunities are expected to emerge, according to the report.

Among the factors driving the RPM market are an increase in the prevalence of chronic health conditions; concerns about readmissions; looming physician shortages; and technological advancements.

But cost concerns and a lack of standard reimbursement models are holding back the adoption RPM tools.

"We appear to be at an opportune time for RPM systems to thrive," said Frost & Sullivan principal analyst Victor Camlek. "The convergence of biometric monitoring and sensors, along with a wider end-user base of technology-comfortable patients will create an environment where clinical grade RPM will expand incrementally. A move from an episodic model towards a dynamic continuous care model will enable the possibility of early detection and response of healthcare stakeholders to preventable crisis events."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.